Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte (Nasdaq: PCVX) management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
A live webcast will be available via the company Investor site and a replay will be accessible for approximately 30 days after the conference.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCVX
In the Feb 6 session, PCVX gained 4.16%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Gross offering proceeds
- $632.5 million
- Underwritten public offering closed Feb 2, 2026
- Shares offered
- 12,650,000 shares
- Public offering including underwriters’ option
- Shares in offering
- 11,000,000 shares
- Primary offering at $50.00 per share
- Offering price
- $50.00 per share
- Common stock public offering
- Net loss
- $212.8 million
- Q3 2025 net loss
- Cash, cash equivalents and investments
- $2.67 billion
- As of September 30, 2025
- Operating cash use
- $430.7 million
- First nine months of 2025
- Conference time
- 1:30 p.m. ET / 10:30 a.m. PT
- Guggenheim Emerging Outlook: Biotech Summit fireside chat
Historical Context
-
Closed underwritten public offering raising $632.5M gross at $50 per share.
-
Priced $550M underwritten common stock offering at $50 per share.
-
Announced proposed $500M common stock and pre-funded warrant offering.
-
Advanced adult and infant VAX-31 programs and outlined Phase 3 timelines.
-
Dosed first participants in pivotal OPUS Phase 3 trial of VAX-31 in adults.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.